Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oculis Holding AG filings document its reporting as a Swiss foreign private issuer and its development-stage biopharmaceutical business in ophthalmology and neuro-ophthalmology. Form 6-K reports furnish IFRS consolidated financial statements, interim financial statements, management discussion and analysis, annual reports, press releases, annual general meeting invitations, proxy materials, and current company updates.
The filing record also covers ordinary-share capital structure, registration statement references on Form F-3 and Form S-8, at-the-market offering arrangements, sales agreements, incorporation by reference, shareholder voting matters, and governance materials. Clinical and regulatory disclosures relate to OCS-01, Privosegtor, Licaminlimab, related development programs, liquidity, operating expenses, and the risks associated with advancing investigational drug candidates.